News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mercator Therapeutics and Pepscan Establish Research and Licensing Collaboration


1/3/2011 9:36:18 AM

WALTHAM, Mass. & LELYSTAD, the Netherlands--(BUSINESS WIRE)--Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator’s ‘Homing Peptides’ using Pepscan’s proprietary CLIPS technology.

Read at BioSpace.com


comments powered by Disqus
Pepscan
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES